I was listening to the business of biotech podcast while running on Monday, where Allan Shaw a biotech CFO was being interviewed. He made a point around how he would pick a great team with mediocre asset before a great asset with mediocre team, as the great team will find a way to create value.
I think in this case, we have an all-star team for this specific space, and an asset which has been promising thus far and appears to be differentiated. I am excited for the future!
I was listening to the business of biotech podcast while running...
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.0¢ |
Change
0.002(11.1%) |
Mkt cap ! $17.25M | |||
| Open | High | Low | Value | Volume |
| 1.9¢ | 2.0¢ | 1.9¢ | $26.18K | 1.372M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 736556 | 1.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.0¢ | 1462067 | 5 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| CHM (ASX) Chart |